Page last updated: 2024-12-06

ciprofloxacin hydrochloride anhydrous

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ciprofloxacin hydrochloride anhydrous is a synthetic broad-spectrum antibiotic that belongs to the fluoroquinolone class. It is commonly used to treat bacterial infections. It was first synthesized in 1980 and is effective against a wide range of bacteria, including gram-negative and gram-positive bacteria. Its mechanism of action involves inhibiting the activity of bacterial DNA gyrase, an enzyme essential for DNA replication. Ciprofloxacin hydrochloride anhydrous is important because it is effective against a wide range of bacteria and is often used when other antibiotics are ineffective. It is studied because it is a relatively safe and effective antibiotic, but there are concerns about the potential for resistance development. The synthesis involves a series of chemical reactions, starting with a fluorinated quinolone derivative. The compound is usually administered orally or intravenously. It is absorbed well from the gastrointestinal tract, and it is widely distributed throughout the body. It is metabolized in the liver and excreted in the urine. Side effects of ciprofloxacin hydrochloride anhydrous can include nausea, vomiting, diarrhea, and headache. It can also cause allergic reactions, and it is not recommended for use in pregnant or breastfeeding women. '

Cross-References

ID SourceID
PubMed CID62999
CHEMBL ID1202
CHEBI ID310388
SCHEMBL ID42310
MeSH IDM0584080

Synonyms (63)

Synonym
nsc-620634
ciprofloxacin hydrochloride
93107-08-5
PRESTWICK_67 ,
BIM-0048462.P001
ciprofloxacin hydrochloride anhydrous
C2227
bay-o-9867
ciprofloxacini hydrochloridum
CHEMBL1202
AKOS005111008
HMS1568G08
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
ciprofloxacin hcl
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride
86483-48-9
4-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinolin-7-yl)-piperazin-1-ium; chloride
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid; hydrochloride
ciprofloxacin hydrochloride (anh.)
chebi:310388 ,
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hcl
1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid hydrochloride
dtxsid1047788 ,
tox21_110712
0mp32mfp6c ,
FT-0623850
FT-0623851
EPITOPE ID:174846
S5008 ,
ciprofloxacin hydrochloride [who-dd]
SCHEMBL42310
tox21_110712_1
NCGC00016959-06
KS-5012
DIOIOSKKIYDRIQ-UHFFFAOYSA-N
ciprofloxacine hydrochloride
ciprofloxacin hcl/lactate
F0001-2378
cambridge id 5807784
Q-200860
AC-23972
ciprofloxacin hydrochloride (1:x)
mfcd00079044
CS-8134
ciprofloxacin (monohydrochloride)
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid xhydrochloride
HY-B0356A
Q27105154
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hcl
BCP14336
BCP13634
A16969
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydrochloride
cpx; cetraxal; ciloxan; cipro; bay-09867 hydrochloride
SB73037
H10663
A859872
cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, monohydrochloride
93107-08-5 (hcl)
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylicacidxhydrochloride
3-quiolinecarboxylic acid
clprofloxacin hydrochloride
ciprofloxacin hci

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
antibacterial drugA drug used to treat or prevent bacterial infections.
topoisomerase IV inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase IV, which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Drug ADME6387
Ciprofloxacin ADME513

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GALC proteinHomo sapiens (human)Potency0.707928.183828.183828.1838AID1159614
TDP1 proteinHomo sapiens (human)Potency7.36780.000811.382244.6684AID686978; AID686979
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.07950.01237.983543.2770AID1346984
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.29990.000229.305416,493.5996AID743080
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency21.75600.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (179)

Assay IDTitleYearJournalArticle
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID65197In vitro antibacterial activity was measured against nalidixic acid resistant strain 3 from Escherichia coli KC-141992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID227855In vitro antibacterial activity against staphylococcus epidermidis IAM 1296, (gram-positive)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID71057Concentration which causes 50% of the gyrase (Escherichia coli H560)-mediated maximal DNA cleavage.1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1678767Antibacterial activity against Enterococcus faecalis ATCC 51299 using DMSO as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID197990Minimum concentration required to prevent the growth of multiply resistant (MRSA) Staphylococcus aureus strain A01711999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID600462Oral bioavailability in rat2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.
AID162926Minimum concentration required to prevent the growth of Pseudomonas aeruginosa strain 282151999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1740320Antimicrobial activity against Escherichia coli ATCC 8739 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID1740328Antifungal activity against Candida albicans ATCC 10231 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID78704The inhibitory activity was measured for the supercoiling activity of DNA gyrase isolated from Escherichia coli K-12 C600.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID207234In vivo efficacy against Staphylococcus aureus NCTC-10649M after oral administration1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1678780Antibacterial activity against Enterococcus faecalis ATCC 51299 using Cyrene as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID65202In vitro antibacterial activity against Escherichia coli KC-14, Ec(K), (gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID68412Minimum concentration required to prevent the growth of vancomycin resistant (VanA) Enterococcus faecium strain A23201999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1678766Antibacterial activity against Escherichia coli ATCC 25922 using DMSO as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID206604In vitro antibacterial activity against gram-positive organism Staphylococcus aureus ATCC 6538p1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID66102Inhibitory activity against enterococcus faecium Van A1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID197991Minimum concentration required to prevent the growth of multiply resistant (MRSA) and cipro resistant (Cipro-R) Staphylococcus aureus strain A28001999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID67589Minimum concentration required to prevent the growth of nonresistant stock strain Enterococcus faecalis 51299 from American Type Culture Collection (ATCC)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1740325Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID65383In vitro antibacterial activity against Escherichia coli NIHJ JC-2,(gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID206355Minimum concentration required to prevent the growth of multiply resistant Staphylococcus epidermidis (MRSE) coag.-neg. Staph. A02441999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1678763Antibacterial activity against Pseudomonas aeruginosa ATCC 27893 using cyrene as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1740326Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 9253 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID206353Minimum concentration required to prevent the growth of multiply resistant Staphylococcus epidermidis (MRSE) and cipro resistant (Cipro-R) coag.-neg. Staph. A02471999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID206603In vitro antibacterial activity against gram-positive organism Staphylococcus aureus 17751996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID68824In vivo efficacy against Escherichia coli JUHL after oral administration1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1678758Induction of ROS mediated programmed cell death in Escherichia coli ATCC 25922 at 2 times MIC preincubated for 90 mins followed by replating on LB agar containing DMSO measured after overnight incubation by colony counting method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID68388In vitro antibacterial activity against gram-positive organism Enterococcus faecium ATCC 80431996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID197988Minimum concentration required to prevent the growth of nonresistant stock strain Enterococcus faecalis 29213 from American Type Culture Collection (ATCC)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID96440Minimum concentration required to prevent the growth of cipro resistant (Cipro-I) Klebsiella pneumoniae strain AM1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID96404In vitro antibacterial activity against gram-negative organism Klebsiella pneumoniae ATCC 80451996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID94142Minimum concentration required to prevent the growth of cipro resistant (Cipro-I) Klebsiella pneumoniae strain AM1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID206356Minimum concentration required to prevent the growth of multiply resistant Staphylococcus epidermidis (MRSE) coag.-neg. Staph. A02451999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1678757Induction of ROS mediated programmed cell death in Escherichia coli ATCC 25922 at 2 times MIC preincubated for 90 mins followed by replating on LB agar containing cyrene measured after overnight incubation by colony counting method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1740319Antimicrobial activity against Escherichia coli NCTC 11954 producing penicillinase assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID1678761Antibacterial activity against Acinetobacter baumannii ATCC 19606 using cyrene as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID600468Thermodynamic aqueous solubility of the compound in phosphate buffer at pH 7.42011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.
AID93998Minimum concentration required to prevent the growth of cipro resistant (Cipro-I) Klebsiella oxytoca strain A35301999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID198010Minimum concentration required to prevent the growth of multiply resistant Staphylococcus epidermidis (MRSE) coag.-neg. Staph. A02451999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID197989Minimum concentration required to prevent the growth of multiply resistant (MRSA) Staphylococcus aureus strain A01701999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1740323Antimicrobial activity against Salmonella enterica ATCC 13312 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID1740332Antifungal activity against Penicillium chrysogenum ATCC 10106 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID23806Plasma half-life in rats after an oral dose of 5 mg/kg1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID198011Minimum concentration required to prevent the growth of multiply resistant Staphylococcus epidermidis (MRSE) and cipro resistant (Cipro-R) coag.-neg. Staph. A02471999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID67590Minimum concentration required to prevent the growth of vancomycin resistant (VanA) Enterococcus faecalis strain A04011999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID65381In vitro antibacterial activity against Enterococcus faecalis IID 682,Ec (N),(gram-positive)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID208771In vivo efficacy against Strep. administration1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID65196In vitro antibacterial activity was measured against nalidixic acid resistant strain 2 from Escherichia coli KC-141992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID65073In vitro antibacterial activity was measured against nalidixic acid resistant strain 5 from Escherichia coli KC-141992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID209477In vitro antibacterial activity against gram-positive organism Streptococcus pyogenes EES611996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1678769Antibacterial activity against Staphylococcus aureus ATCC 43300 using DMSO as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1678759Antibacterial activity against Klebsiella pneumoniae ATCC 700603 using cyrene as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID104181Minimum concentration required to prevent the growth of Listeria monocytogenes strain A01821999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID65201In vitro antibacterial activity was measured against nalidixic acid resistant strain 7 from Escherichia coli KC-141992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID1678765Antibacterial activity against Escherichia coli ATCC 25922 using cyrene as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID207654Minimum concentration required to prevent the growth of multiply resistant (MRSA) Staphylococcus aureus strain A01701999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID356774Inhibition of DNA synthesis in Escherichia coli assessed as incorporation of [3H]thymidine at 0.25 ug/mL by LKB Betaplate scintillation counter relative to control2001Journal of natural products, Jul, Volume: 64, Issue:7
Biological and mechanistic activities of xanthorrizol and 4-(1',5'-dimethylhex-4'-enyl)-2-methylphenol isolated from Iostephane heterophylla.
AID206605In vitro antibacterial activity against gram-positive organism Staphylococcus aureus NCTC-10649M1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1740321Antimicrobial activity against Escherichia coli O157:H7 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID453815Antibacterial activity against Bacillus anthracis deltaANR after 14 hrs by microplate alamar blue assay2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Natural product leads for drug discovery: isolation, synthesis and biological evaluation of 6-cyano-5-methoxyindolo[2,3-a]carbazole based ligands as antibacterial agents.
AID65394Minimum concentration required to prevent the growth of Enterococcus faecium strain A1745 with characteristics VanA1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID164082In vivo efficacy against Pseudomonas aeruginosa 5007 after subcutaneous administration1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID63881Minimum concentration required to prevent the growth of cipro resistant (Cipro-R) Escherichia coli strain A35291999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID197992Minimum concentration required to prevent the growth of multiply resistant (MRSA) and cipro resistant (Cipro-R) Staphylococcus aureus strain A20431999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID18008Oral bioavailability in rat (dose 5 mg/kg)1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1740329Antifungal activity against Aspergillus flavus ATCC 9643 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID69167Minimum concentration required to prevent the growth of cipro resistant (Cipro-R) Escherichia coli strain AA1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1678768Antibacterial activity against Staphylococcus aureus ATCC 43300 using Cyrene as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID198013Minimum concentration required to prevent the growth of multiply resistant Staphylococcus epidermidis (MRSE) coag.-neg. Staph. A02441999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID71097In vitro antibacterial against gram-negative organism Escherichia coli JUHL1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID68413Minimum concentration required to prevent the growth of vancomycin resistant (VanB) Enterococcus faecium strain A08031999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID163963In vitro antibacterial activity against Pseudomonas aeruginosa IFO 3445,Pa(I),(gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID151054Minimum concentration required to prevent the growth of Pseudomonas aeruginosa strain 282451999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID600463Inhibition of Escherichia coli H560 DNA gyrase mediated DNA cleavage2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.
AID67572Inhibitory activity against enterococcus faecalis Van B1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1678760Antibacterial activity against Klebsiella pneumoniae ATCC 700603 using DMSO as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID14244Maximum plasma concentration in rats after an oral dose of 5 mg/kg1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID164083In vivo efficacy against Pseudomonas aeruginosa 5007 following p.o. administration.1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1678764Antibacterial activity against Pseudomonas aeruginosa ATCC 27893 using DMSO as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1740324Antimicrobial activity against Pseudomonas aeruginosa ATCC 9627 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID206354Minimum concentration required to prevent the growth of multiply resistant Staphylococcus epidermidis (MRSE) and cipro resistant (Cipro-R) coag.-neg. Staph. A02481999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID66731In vitro antibacterial activity against gram-negative organism Enterococcus aerogenes ATCC 130481996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID163889In vitro antibacterial activity against gram-negative organism Prov. stuartii CMX-6401996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID96284Minimum concentration required to prevent the growth of Listeria monocytogenes strain A01831999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID416327Antibacterial activity against Bacillus anthracis Sterne2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs).
AID69168Minimum concentration required to prevent the growth of nonresistant stock Escherichia coli strain 25922 from American Type Culture Collection (ATCC)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID68411Minimum concentration required to prevent the growth of vancomycin resistant (VanA) Enterococcus faecium strain A17451999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1678762Antibacterial activity against Acinetobacter baumannii ATCC 19606 using DMSO as solvent by broth microdilution method2020RSC medicinal chemistry, Jan-01, Volume: 11, Issue:1
Cyrene™ is a green alternative to DMSO as a solvent for antibacterial drug discovery against ESKAPE pathogens.
AID1740327Antimicrobial activity against Listeria monocytogenes ATCC 19115 assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID65075In vitro antibacterial activity was measured against nalidixic acid resistant strain 1 from Escherichia coli KC-141992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID67586Minimum concentration required to prevent the growth of high level gentamicin and beta- lactamase resistant (HLGR, BLA+) Enterococcus faecalis strain A00891999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID68410Minimum concentration required to prevent the growth of nonresistant stock strain Enterococcus faecium 19434 from American Type Culture Collection (ATCC)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID63879Minimum concentration required to prevent the growth of nonresistant stock Escherichia coli strain 25922 from American Type Culture Collection (ATCC)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID223835In vitro antibacterial activity against Pseudomonas aeruginosa E-2,Pa(E),(gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID227851In vitro antibacterial activity against staphylococcus aureus IID 803,(gram-positive)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID65055In vitro antibacterial activity for the supercoiling activity of DNA gyrase isolated from Escherichia coli K-12 C600.1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID207656Minimum concentration required to prevent the growth of multiply resistant (MRSA) and cipro resistant (Cipro-R) Staphylococcus aureus strain A28001999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1740331Antifungal activity against Stachybotrys chartarum IBT 7711 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID356981Inhibition of protein synthesis in Escherichia coli assessed as incorporation of [3H]amino acid at 0.25 ug/mL by LKB Betaplate scintillation counter relative to control2001Journal of natural products, Jul, Volume: 64, Issue:7
Biological and mechanistic activities of xanthorrizol and 4-(1',5'-dimethylhex-4'-enyl)-2-methylphenol isolated from Iostephane heterophylla.
AID67591Minimum concentration required to prevent the growth of vancomycin resistant (VanA) Enterococcus faecalis strain A04021999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID67722Minimum concentration required to prevent the growth of vancomycin resistant (VanB) Enterococcus faecalis strain A10811999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID96283Minimum concentration required to prevent the growth of Listeria monocytogenes strain A01821999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID1740333Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID68414Minimum concentration required to prevent the growth of vancomycin resistant (VanB) Enterococcus faecium strain A10871999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID68826In vivo efficacy against Escherichia coli JUHL by subcutaneous administration1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID207235In vivo efficacy against Staphylococcus aureus NCTC-10649M after subcutaneous administration1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID65200In vitro antibacterial activity was measured against nalidixic acid resistant strain 6 from Escherichia coli KC-141992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID162927Minimum concentration required to prevent the growth of Pseudomonas aeruginosa strain 282451999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID20906Aqueous solubility in pH 7.4 phosphate buffer (0.05 M) at 37 degree C1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID69050Minimum concentration required to prevent the growth of cipro resistant (Cipro-R) Escherichia coli strain A35291999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID208916In vitro antibacterial activity against gram-positive organism Streptococcus bovis A-51691996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID207655Minimum concentration required to prevent the growth of multiply resistant (MRSA) Staphylococcus aureus strain A01711999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID227850In vitro antibacterial activity against staphylococcus aureus FDA 209P JC-1,Sa(F)(gram-positive)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID1740330Antifungal activity against Fusarium solani ATCC 36031 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID198012Minimum concentration required to prevent the growth of multiply resistant Staphylococcus epidermidis (MRSE) and cipro resistant (Cipro-R) coag.-neg. Staph. A02481999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID220994In vitro antibacterial activity against klebsiella pneumoniae B54,Kp,(gram-negative)1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID207657Minimum concentration required to prevent the growth of multiply resistant (MRSA) and cipro resistant (Cipro-R) Staphylococcus aureus strain A20431999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID165192In vitro antibacterial activity against gram-negative organism Pseudomonas aeruginosa DPHD-28621996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID1740322Antimicrobial activity against fluoroquinolone-resistant Escherichia coli assessed as inhibition of microbial growth incubated for 24 hrs by microbroth dilution method2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and antimicrobial evaluation of novel glycosylated-fluoroquinolones derivatives.
AID69049Minimum concentration required to prevent the growth of cipro resistant (Cipro-R) Escherichia coli strain A32281999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID67721Minimum concentration required to prevent the growth of vancomycin resistant (VanB) Enterococcus faecalis strain A10791999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID104182Minimum concentration required to prevent the growth of Listeria monocytogenes strain A01831999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID151053Minimum concentration required to prevent the growth of Pseudomonas aeruginosa strain 282151999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID67588Minimum concentration required to prevent the growth of nonresistant stock strain Enterococcus faecalis 29212 from American Type Culture Collection (ATCC)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID67587Minimum concentration required to prevent the growth of high level gentamicin and beta- lactamase resistant (HLGR, BLA+) Enterococcus faecalis strain A00901999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID356974Inhibition of RNA synthesis in Escherichia coli assessed as incorporation of [3H]uridine at 0.25 ug/mL by LKB Betaplate scintillation counter relative to control2001Journal of natural products, Jul, Volume: 64, Issue:7
Biological and mechanistic activities of xanthorrizol and 4-(1',5'-dimethylhex-4'-enyl)-2-methylphenol isolated from Iostephane heterophylla.
AID208769In vivo efficacy against Strep. administration1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID207659Minimum concentration required to prevent the growth of nonresistant stock strain Enterococcus faecalis 29213 from American Type Culture Collection (ATCC)1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID165191In vitro antibacterial activity against gram-negative organism Pseudomonas aeruginosa 50071996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.
AID65198In vitro antibacterial activity was measured against nalidixic acid resistant strain 4 from Escherichia coli KC-141992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Synthesis and antibacterial activity of new tetracyclic quinolone antibacterials.
AID63882Minimum concentration required to prevent the growth of cipro resistant (Cipro-R) Escherichia coli strain AA1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID95877Minimum concentration required to prevent the growth of cipro resistant (Cipro-I) Klebsiella oxytoca strain A35301999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID64250Minimum concentration required to prevent the growth of cipro resistant (Cipro-R) Escherichia coli strain A32281999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (13.04)18.2507
2000's3 (13.04)29.6817
2010's9 (39.13)24.3611
2020's8 (34.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.70 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]